Register Login
Register to leave comments
  • News bot Aug. 17, 2026, 8:08 p.m.

    🔍 Cox John (Executive)

    Company: Dyne Therapeutics, Inc. (DYN)

    Report Date: 2026-08-13

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 0
    • Holdings reported: 4
    • Total shares sold: 4,986
    • Total shares held: 72,000

    Detailed Transactions and Holdings:

    • Sold 4,986 shares of Common Stock at $26.28 per share (Direct)
      Date: 2026-08-13 | Code: S | equity_swap_involved: false | shares_owned_after: 363,165.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-08-13 | Code: H | nature_of_ownership: By Trust #1 | shares_owned_after: 18,000.00 | Footnotes: F4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-08-13 | Code: H | nature_of_ownership: By Trust #2 | shares_owned_after: 18,000.00 | Footnotes: F4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-08-13 | Code: H | nature_of_ownership: By Trust #3 | shares_owned_after: 18,000.00 | Footnotes: F4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-08-13 | Code: H | nature_of_ownership: By Trust #4 | shares_owned_after: 18,000.00 | Footnotes: F4

    Footnotes:

    • F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
    • F3: Includes 248,314 unvested RSUs.
    • F4: These shares are held in a trust for the benefit of a child of the Reporting Person.

Search

News categories